To the question about factors influencing neuromuscular blockade

G.G. Bestaev, V.D. Slepushkin

North-Ossetian State Medical Academy, Vladikavkaz

For correspondence: Georgy Bestaev — assistant of Department of anesthesiology and critical care medicine of North-Ossetian State Medical Academy; e-mail: georbest@mail.ru

For citation: Bestaev GG, Slepushkin VD. To the question about factors influencing neuromuscular blockade. Alexander Saltanov Intensive Care Herald. 2018;2:36–9.

DOI: 10.21320/1818-474X-2018-2-36-39


It has long been known that the duration of the action of muscle relaxants is affected by a variety of factors, and to a greater extent this effect is observed when using non-depolarizing muscle relaxants of medium and long duration. Surprisingly, factors, influencing neuromuscular block, are not becoming the subject of scientific discussion and are not reflected in modern literature. It is absolutely obvious at the same time that the study of quantitative dynamics of neuromuscular block represents a significant scientific and practical interest. In the given literature review the most important factors will be considered and discussed.

Keywords: factors, muscle relaxants, neuromuscular block, inhalational anesthetics, smoking, electrolytes, temperature, circadian rhythm

Received: 07.02.2018


References

  1. Бестаев Г.Г., Слепушкин В.Д. Миорелаксанты: от кураре до круарона. Владикавказ, 2016. [Bestaev G.G., Slepushkin V.D. Muscle relaxants: from curare to kruaron. Vladikavkaz,2016. (In Russ)]
  2. СлепушкинВ.Д., Бестаев Г.Г. Использование миорелаксантов в анестезиологии и реаниматологии. Москва — Владикавказ, 2017. [Slepushkin V.D., Bestaev G.G. The use of muscle relaxants in anesthesia and resuscitation. Moskva — Vladikavkaz, 2017. (In Russ)]
  3. Багомедов В.Р., Слепушкин В.Д., Тотикова М.Б. Особенности анестезиологического пособия у курящих больных. Актуальные вопросы современной медицины.2012. [Bagomedov V.P., Slepushkin V.D., Totikova M.B. Features anesthetic in smoking patients. Topical issues of modern medicine. 2012. (In Russ)]
  4. Ishigaki S., Ogura T., Kanaya A. Influence of preoperative oral rehydration on arterial plasma rocuronium concentration and neuromuscular blocking effects: A randomized controlled trial. Eur. J. Anaesthesiol. 2017; 34: 16–22.
  5. Saitoh Y., Toyooka H., Amaha K. Recoveries of post-tetanic twitch and train-of-four responses after administration of vecuronium with different inhalation anaeshetics and neuroleptanaesthesia. Br. J. Anaesth. 1993; 70: 402–404.
  6. Bock M., Klippel K., Nitsche B., et al. Rocuronium potency and recovery characteristics during steady-state desflurane, sevoflurane, isoflurane or propofol anaesthesia. Br. J. Anaesth. 2000; 84: 43–47.
  7. Suzuki T., Fukano N., Kitajima O., et al. Normalization of acceleromyographic train-of-four ratio by baseline value for detecting residual neuromuscular block. Br. J. Anaesth. 2006; 96: 44–47.
  8. Pereon Y., Bernard J.M., Nguyen The Tich S., et al. The effects of desflurane on the nervous system: from spinal cord to muscles. Anesth. Analg. 1999; 89: 490–495.
  9. Paul M., Fokt R.M., Kindler C.H., et al. Characterization of the interactions between volatile anesthetics and neuromuscular blockers at the muscle nicotinic acetylcholine receptor. Anesth. Analg. 2002; 95: 362–367.
  10. Cannon J.E., Fahey M.R., Castagnoli K.P., et al. Continuous infusion of vecuronium: the effect of anesthetic agents. Anesthesiology. 1987; 67: 503–506.
  11. Rupp S.M., Miller R.D., Gencarelli P.J. Vecuronium-induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans. Anesthesiology. 1984; 60: 102–105.
  12. Gecarelli P.J., Miller R.D., Eger E.I., et al. Decreasing enflurane concentrations and rf-tubocurarine neuromuscular blockade. Anesthesiology. 1982; 56: 192–194.
  13. Wulf H., Kahl M., Ledowski T. Augmentation of the neuromuscular blocking effects of cisatracurium during desflurane, sevoflurane, isoflurane or total i.v. anaesthesia. Br.J. Anaesth. 1988; 80: 308–312.
  14. СуиниБ.П., Грейлинг М. Курение и анестезия: фармакология и последствия. Регионарная анестезия и лечение острой боли. 2011; 5(4): 52–60. [Sweeney B.P., Grayling M. Smoking and anaesthesia: the pharmacological implications. Regional anesthesia and treatment of acute pain. 2011; 5(4): 52–60. (In Russ)]
  15. Beckers S., Camu F. The anesthetic risk of tobacco smoking. Acta Anaesthesiologica Belgica. 1991; 42: 45–56.
  16. Rodrigo C. The effects of cigarette smoking on anesthesia. Anesthesia Progress. 2000; 47: 143–150.
  17. Benowitz N.L. Pharmacological aspects of cigarette smoking and nicotine. New England Journal of Medicine. 1988; 319: 1318–1330.
  18. Teiria H., Rautoma P., Yli-Hankala A. Effect of smoking on dose requirements for vecuronium. Br. J. of Anaesthesia. 1996; 76: 154–155.
  19. Latorre F., de Almeida M.C., Stanek A., et al. The interaction between rocuronium and smoking. The effect of smoking on neuromuscular transmission after rocuronium. Anaesthesist. 1997; 46: 493–495.
  20. Puhringer F.K., Keller P., Lockinger A., et al. Smoking does not alter the dose-requirements and the pharmacodynamics of rocuronium. Can. J. Anaesthesia. 2000; 47: 347–349.
  21. Puura A.I., Rorarius M.G., Laippala P., et al. Does abstinence from smoking or a transdermal nicotine system influence atracurium-induced neuromuscular block? Anesthesia and Analgesia. 1998; 87: 430–433.
  22. Fuchs-Buder T. et al. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br. J. Anaesth. 1995; 74(4): 405–409.
  23. Kussman B. et al. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br. J. Anaesth. 1997; 79(1): 122–124.
  24. Czarnetzki C. et al. Time course of rocuronium-induced neuromuscular block after pretreatment with magnesium sulphate: a randomised study. Acta Anaesthesiol. Scand. 2010; 54(3): 299–306.
  25. Kim M.H. et al. A randomised controlled trial comparing rocuronium priming, magnesium pretreatment and a combination of the two methods. Anaesthesia. 2012; 67(7): 748–754.
  26. Waud B.E., Waud D.R. Interaction of calcium and potassium with neuromuscular blocking agents. Br. J. Anaesth. 1980; 52: 863–866.
  27. Naquib M., Lien C.A. Pharmacology of muscle relaxants and their antagonists. In: Miller’s Anesthesia. 6thed. Ed. R.D. Miller. New York: Churchill Livingstone, 2005: 481–572.
  28. Biro K. Effects of respiratory and metabolic alkalosis and acidosis on pipecuronium neuromuscular block. Eur. J. Pharmacol. 1988; 154: 329–333.
  29. Adamus M., Hrabalek L., Wanek T., et al. Influence of age and gender on the pharmacodynamic parameters of rocuronium during total intravenous anesthesia. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2011; 155: 347–353.
  30. Craig R.G., Hunter J.M. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia. 2009; 64: 55–65.
  31. Dahaba A.A., Perelman S.I., Moskowitz D.M., et al. Geographic regional differences in rocuronium bromide dose-response relation and time course of action: an overlooked factor in determining recommended dosage. Anesthesiology. 2006; 104: 950–953.
  32. Soltész S., Fraisl P., Noé K.G., et al. Dexamethasone decreases the duration of rocuronium-induced neuromuscular block: a randomised controlled study. Eur.J. Anaesthesiol. 2014; 31: 417–422.